Single-Treatment, Study of Percutaneous-Temperature Controlled-RF Electrocoagulation on Axilla Tissue

5Inclusion Criteria * Male or female between the age of 18 and 50 inclusive * Focal, visible excess sweating present for at least 6 months * Self-reported excess sweating that becomes visible through clothing and has a negative psychosocial impact on the subject's quality of life * At least any two of the following: * Bilateral and symmetrical excessive sweating * Impairs activities of daily life * At least one episode per week * Age of onset \<25 years * Desire to reduce / improve the condition * Willing to refrain the use of deodorant products containing "Aluminum Chloride" one to two weeks prior to treatment and for the duration of the study * Females of childbearing potential who are sexually active must be willing to use an approved method of birth control during study participation * Cooperative, reliable, and able to read and comprehend English * Able to read, understand, sign and date the informed consent document (English only) * Able and willing to comply with the schedule visit(s) and study requirements. Exclusion Criteria Subjects presenting with any of the following will not be included in the study * Prior use of botulinum toxin injections into axilla within the last 6 months * Priory Miradry treatments * Prior surgical dissection, curettage or liposuction * Current or prior sympathectomy * Current or prior laser therapy to axilla for hyperhidrosis * Female subject in menopause stage * Current use of oral medications such as oxybutynin, glycopyrolate, clonazepam, clonidine, phenoxybenzamine or propranolol * Use within 7 days preceding surgery of ibuprofen, , non-steroidal anti-inflammatory products, or any products including herbals and supplements that could interfere with the clinical assessments of this study (other than drugs used for anesthesia) * Subjects who have a pacemaker, implantable defibrillators, metal stents, implants or other monitoring equipment * History or current injury to the axilla or nearby anatomical areas. * Clinically significant wounds, lesions or acute infections including, dermatitis, lupus or other autoimmune disease affecting the dermis * Pregnant or planning pregnancy prior to the end of study participation * History or current diagnosis of cancer of any type * History of uncontrolled cardiovascular disease(i.e. myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease) * Known hypersensitivity to local anesthetic medications * History, or current bleeding disorders (i.e. hemophilia or von Willebrand disease), or anticipated treatment with prescription anticoagulants * History of AIDs/HIV * Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years * Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and/or ability to follow study subject requirement and/or record the necessary study measurements * Any family member of the investigator or investigational staff, or an employee of the investigator. * Participation in any other investigational study within 30 days prior to consent;